Cargando…
A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients with High/High-intermediate risk Diffuse Large B-Cell Lymphoma
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5214342/ https://www.ncbi.nlm.nih.gov/pubmed/27654851 http://dx.doi.org/10.1038/leu.2016.255 |
| _version_ | 1782491600466739200 |
|---|---|
| author | Reddy, Nishitha M. Greer, John P. Morgan, David S. Chen, Heidi Park, Steven I. Richards, Kristy L. |
| author_facet | Reddy, Nishitha M. Greer, John P. Morgan, David S. Chen, Heidi Park, Steven I. Richards, Kristy L. |
| author_sort | Reddy, Nishitha M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5214342 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2016 |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-52143422017-03-22 A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients with High/High-intermediate risk Diffuse Large B-Cell Lymphoma Reddy, Nishitha M. Greer, John P. Morgan, David S. Chen, Heidi Park, Steven I. Richards, Kristy L. Leukemia Article 2016-09-22 2017-01 /pmc/articles/PMC5214342/ /pubmed/27654851 http://dx.doi.org/10.1038/leu.2016.255 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
| spellingShingle | Article Reddy, Nishitha M. Greer, John P. Morgan, David S. Chen, Heidi Park, Steven I. Richards, Kristy L. A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients with High/High-intermediate risk Diffuse Large B-Cell Lymphoma |
| title | A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients with High/High-intermediate risk Diffuse Large B-Cell Lymphoma |
| title_full | A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients with High/High-intermediate risk Diffuse Large B-Cell Lymphoma |
| title_fullStr | A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients with High/High-intermediate risk Diffuse Large B-Cell Lymphoma |
| title_full_unstemmed | A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients with High/High-intermediate risk Diffuse Large B-Cell Lymphoma |
| title_short | A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients with High/High-intermediate risk Diffuse Large B-Cell Lymphoma |
| title_sort | phase ii randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large b-cell lymphoma |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5214342/ https://www.ncbi.nlm.nih.gov/pubmed/27654851 http://dx.doi.org/10.1038/leu.2016.255 |
| work_keys_str_mv | AT reddynishitham aphaseiirandomizedstudyoflenalidomideorlenalidomideandrituximabasmaintenancetherapyfollowingstandardchemotherapyforpatientswithhighhighintermediateriskdiffuselargebcelllymphoma AT greerjohnp aphaseiirandomizedstudyoflenalidomideorlenalidomideandrituximabasmaintenancetherapyfollowingstandardchemotherapyforpatientswithhighhighintermediateriskdiffuselargebcelllymphoma AT morgandavids aphaseiirandomizedstudyoflenalidomideorlenalidomideandrituximabasmaintenancetherapyfollowingstandardchemotherapyforpatientswithhighhighintermediateriskdiffuselargebcelllymphoma AT chenheidi aphaseiirandomizedstudyoflenalidomideorlenalidomideandrituximabasmaintenancetherapyfollowingstandardchemotherapyforpatientswithhighhighintermediateriskdiffuselargebcelllymphoma AT parksteveni aphaseiirandomizedstudyoflenalidomideorlenalidomideandrituximabasmaintenancetherapyfollowingstandardchemotherapyforpatientswithhighhighintermediateriskdiffuselargebcelllymphoma AT richardskristyl aphaseiirandomizedstudyoflenalidomideorlenalidomideandrituximabasmaintenancetherapyfollowingstandardchemotherapyforpatientswithhighhighintermediateriskdiffuselargebcelllymphoma AT reddynishitham phaseiirandomizedstudyoflenalidomideorlenalidomideandrituximabasmaintenancetherapyfollowingstandardchemotherapyforpatientswithhighhighintermediateriskdiffuselargebcelllymphoma AT greerjohnp phaseiirandomizedstudyoflenalidomideorlenalidomideandrituximabasmaintenancetherapyfollowingstandardchemotherapyforpatientswithhighhighintermediateriskdiffuselargebcelllymphoma AT morgandavids phaseiirandomizedstudyoflenalidomideorlenalidomideandrituximabasmaintenancetherapyfollowingstandardchemotherapyforpatientswithhighhighintermediateriskdiffuselargebcelllymphoma AT chenheidi phaseiirandomizedstudyoflenalidomideorlenalidomideandrituximabasmaintenancetherapyfollowingstandardchemotherapyforpatientswithhighhighintermediateriskdiffuselargebcelllymphoma AT parksteveni phaseiirandomizedstudyoflenalidomideorlenalidomideandrituximabasmaintenancetherapyfollowingstandardchemotherapyforpatientswithhighhighintermediateriskdiffuselargebcelllymphoma AT richardskristyl phaseiirandomizedstudyoflenalidomideorlenalidomideandrituximabasmaintenancetherapyfollowingstandardchemotherapyforpatientswithhighhighintermediateriskdiffuselargebcelllymphoma |